Build AI Tumor Segmentation and RECIST Scoring for Mesothelioma CT

1. 1

   Understand the measurement problem

   Mesothelioma's uniquely complex, rind-like tumor shape makes standard RECIST treatment-response measurement difficult and inconsistent for human radiologists. Automated segmentation and scoring can improve accuracy and reduce clinical-trial costs, the aim of the cited Canon Medical Research Europe and Glasgow Pleural Disease Unit collaboration. Ground the product in that specific, hard imaging task.

2. 2

   Acquire annotated CT datasets

   The model needs annotated mesothelioma CT scans with expert tumor delineation and response data, available only through partnerships with radiology departments and pleural-disease centers. Curated, well-labeled imaging data is the core defensible asset. Handle patient data under strict privacy and ethics rules from the outset.

3. 3

   Build and validate the models

   Develop automated tumor segmentation and RECIST-scoring models, then validate against expert radiologist measurements and outcomes across sites, showing improved consistency and accuracy. Multi-site validation is essential for both clinical trust and regulatory approval. Publishing strengthens credibility with radiologists and trial sponsors.

4. 4

   Plan medical-software regulation

   Software that quantifies tumor response for clinical or trial decisions is typically regulated as a medical device, so map the approval pathway early. Frame the tool as supporting radiologists and trial endpoints, not replacing clinical judgment. This adds time and cost but is required for real-world use.

5. 5

   Sell into trials and radiology

   The clearest early value is in clinical trials, where consistent, low-variance response measurement directly reduces cost and improves endpoints, so pharma and contract research organizations are strong first buyers. Radiology departments and cancer centers follow. License per study or per site with integration into imaging workflows.

6. 6

   Expand carefully

   Grow by improving robustness across scanners and protocols, integrating with radiology systems, and potentially extending to other complex tumor types. Maintain validation as data and imaging technology evolve. Keep clinical rigor and regulatory compliance central, because reliability under scrutiny is what sells medical imaging AI.

Do not take our word for the money. Put your own numbers in and see what this idea has to earn before it works. Free, instant, no account needed.